The role and place of dexpanthenol preparations in the prevention and treatment of atopic dermatitis, eczema, and other dermatoses in children and adults: resolution of the Expert Council of Russia

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the consensus opinion of experts on the role of 5% dexpanthenol preparations, particularly the original 5% dexpanthenol cream, in the comprehensive management of patients with inflammatory dermatoses such as atopic dermatitis and eczema. The material was prepared based on the results of the Expert Council held on December 17, 2025. The article reviews current concepts of the pathogenesis of these diseases with an emphasis on the central role of epidermal barrier disruption. The main approaches to restoring the skin barrier within existing therapy are described. Current clinical guidelines are analyzed and problem areas related to algorithms for the use of preparations that restore skin barrier function are identified. An overview of the evidence base for the multifaceted action of 5 % dexpanthenol, which has regenerating, anti-inflammatory, and epidermal barrier-restoring effects, is presented. The place of 5 % dexpanthenol in the treatment of atopic dermatitis is defined: as monotherapy in mild forms, and as part of combination and sequential therapy in moderate-to-severe cases. The final part of the paper formulates practical recommendations for the inclusion of dexpanthenol medicinal products in clinical algorithms for patient management.

About the authors

Margarita R. Rakhmatulina

State Research Center of Dermatovenereology and Cosmetology

Author for correspondence.
Email: rahmatulina@cnikvi.ru
ORCID iD: 0000-0003-3039-7769
SPIN-code: 6222-8684

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Elena R. Araviyskaya

I.P. Pavlov First Saint Petersburg State Medical University

Email: arelenar@mail.ru
ORCID iD: 0000-0002-6378-8582
SPIN-code: 9094-9688

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

Olga G. Elisyutina

National Research Center — Institute of Immunology Federal Medical-Biological Agency; RUDN University

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow

Larisa S. Kruglova

Central State Medical Academy

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Olga I. Letyaeva

South-Ural State Medical University

Email: olga-letyaeva@yandex.ru
ORCID iD: 0000-0002-9085-6229
SPIN-code: 3312-3150

MD, Dr. Sci. (Medicine)

Russian Federation, Chelyabinsk

Gennady A. Novik

Saint-Petersburg State Pediatric Medical University

Email: ga_novik@mail.ru
ORCID iD: 0000-0002-7571-5460
SPIN-code: 6289-0209

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

Irina O. Smirnova

Saint-Petersburg State University

Email: driosmirnova@yandex.ru
ORCID iD: 0000-0001-8584-615X
SPIN-code: 5518-6453

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

Evgeny V. Sokolovskiy

I.P. Pavlov First Saint Petersburg State Medical University

Email: s40@mail.ru
ORCID iD: 0000-0001-7610-6061
SPIN-code: 6807-7137

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

Olga B. Tamrazova

Russian Medical Academy of Continuous Professional Education

Email: anait_tamrazova@mail.ru
ORCID iD: 0000-0003-3261-6718
SPIN-code: 5476-8497

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Elena S. Fedenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762. doi: 10.1038/jid.2011.393
  2. Lytkina EA, Potekaev NN, Bilalova UG, et al. The quality of life of the patients presenting with atopic dermatitis and their compliance with external therapy. Russian Journal of Clinical Dermatology and Venereology. 2011;9(1):45–48. (In Russ.) EDN: QAAOJF
  3. Smolkin YuS, Migacheva NB, Smolkina OYu. Maintenance of remission and prevention of disease flares in children with atopic dermatitis. Position paper of the Association of Children’s Allergists and Immunologists of Russia. Pediatrics. Consilium Medicum. 2020;2:38–45. doi: 10.26442/26586630.2020.2.200149 EDN: DHKOEA
  4. Ebner F, Heller A, Rippke F, et al. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427–433. doi: 10.2165/00128071-200203060-00005 EDN: KHYNQQ
  5. Levasheva SV, Etkina EI, Gurieva LL, et al. Epidermal barrier: from normal to abnormal. Lvrach.ru. 2016;11:13–15. EDN: XWQGCP
  6. Sun N, Ogulur I, Mitamura Y, et al. The epithelial barrier theory and its associated diseases. Allergy. 2024;79(12):3192–3237. doi: 10.1111/all.16318 EDN: ILBJLD
  7. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004
  8. De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773–786. doi: 10.1016/j.jaci.2010.10.018 EDN: WVAKMW
  9. Kuo IH, Yoshida T, De Benedetto A, et al. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266–278. doi: 10.1016/j.jaci.2012.12.1563 EDN: VFFSFV
  10. Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4 EDN: VGXEBT
  11. Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):282–295. doi: 10.1007/s12016-010-8231-1 EDN: SAFZCQ
  12. Атопический дерматит. Клинические рекомендации. 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/265_3 Дата обращения: 08.05.2026
  13. Экзема. Клинические рекомендации. 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/246_3 Дата обращения: 08.05.2026
  14. Kruglova LS, Zaslavsky DV, Pereverzina NO, Sokolovskaya YA. Skin barrier disorders in atopic dermatitis: from the history of the study to the development of “emollients plus”. Pharmateca. 2022;29(14):48–54. (In Russ.) doi: 10.18565/pharmateca.2022.14.48-54 EDN: FLIASK
  15. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892 EDN: CWTNIS
  16. Chikin VV. Topical methylprednisolone aceponate and dexpanthenol in the treatment of patients with atopic dermatitis. Vestnik Dermatologii i Venerologii. 2014;5:112–116 (In Russ.) EDN: TGDMIL
  17. Fedenko ES, Zakharova IN, Zaytseva OV, et al. Practical issues of using emollients for the prevention of exacerbations of atopic dermatitis during the flowering season: expert resolution. Russian Journal of Allergy. 2023;20(2):120–129. (In Russ.). doi: 10.36691/RJA13056 EDN: UJUYBY
  18. Proksch E, Berardesca E, Misery L, et al. Dry skin management: practical approach in light of latest research on skin structure and function. J Dermatolog Treat. 2020;31(7):716–722. doi: 10.1080/09546634.2019.1607024
  19. Wollina U. Conservative procedures in skin reconstitution. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2005;4:Doc 17.
  20. Grenier JF, Aprahamian M, Genot C, Dentinger A. Pantothenic acid (vitamin B5) efficiency on wound healing. Acta Vitaminol Enzymol. 1982;4(1–2):81–85.
  21. Udompataikul M, Limpa-O-Vart D. Comparative trial of 5 % dexpanthenol in water-in-oil formulation with 1 % hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilotstudy. J Drugs Dermatol. 2012;11(3):366–374.
  22. Ogorodova LM, Nagaeva TA, Hodkevich LV. The efficacy of dexpanthenol in complex treatment of atopic dermatitis in children. Pediatric Pharmacology. 2003.,1(3):54–56 (In Russ.) EDN: PWGNXZ
  23. Лукьянов А.М., Музыченко А.П., Эль-Голам М. Опыт сочетанного применения метилпреднизолона ацепоната и декспантенола в терапии атопического дерматита у детей. Международные обзоры: клиническая практика и здоровье. 2015;2:37–49 EDN: TPLAJF
  24. Cho YS, Kim HO, Woo SM, et al. Use of dexpanthenol for atopic dermatitis — benefits and recommendations based on current evidence. J Clin Med. 2022;11(14):3943. doi: 10.3390/jcm11143943 EDN: RQGDIW
  25. Ревякина В.А. Эффективность и безопасность декспантенола в лечении детей с атопическим дерматитом. РМЖ. 2014;22(3):224–227 EDN: SLRODV
  26. Общая характеристика лекарственного препарата Бепантен® крем ЛП-№ (006118)-(РГ-RU) от 03.07.2024.
  27. Hoeger Р, Kinsler V, Yan A, et al. Harper’s textbook of pediatric dermatology. 4th ed. John Wiley & Sons Ltd. 2020. P. 1207–1220.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press, 2026

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.